Hawaii 2024 Regular Session

Hawaii Senate Bill SB1531 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	THE SENATE S.B. NO. 1531 THIRTY-SECOND LEGISLATURE, 2023 S.D. 2 STATE OF HAWAII A BILL FOR AN ACT RELATING TO MENTAL HEALTH. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
2	2
3	3	THE SENATE S.B. NO. 1531
4	4	THIRTY-SECOND LEGISLATURE, 2023 S.D. 2
5	5	STATE OF HAWAII
6	6
7	7	THE SENATE
8	8
9	9	S.B. NO.
10	10
11	11	1531
12	12
13	13	THIRTY-SECOND LEGISLATURE, 2023
14	14
15	15	S.D. 2
16	16
17	17	STATE OF HAWAII
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31	A BILL FOR AN ACT
32	32
33	33
34	34
35	35
36	36
37	37	RELATING TO MENTAL HEALTH.
38	38
39	39
40	40
41	41
42	42
43	43	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
44	44
45	45
46	46
47	47	SECTION 1. The legislature finds that mental health conditions are treated in various ways, depending on the condition, and can include medication, therapy, and psychosocial services. Congress, through the proposed Breakthrough Therapies Act, and the United States Food and Drug Administration have indicated that methylenedioxymethamphetamine, commonly known as MDMA, and psilocybin will be rescheduled to enable its therapeutic use. Methylenedioxymethamphetamine and psilocybin have already been granted the United States Food and Drug Administration's breakthrough therapy designation to fast-track research and potential approval, given their efficacy in treating treatment-resistant depression and post-traumatic stress disorder. These treatments, while effective for certain conditions and patients, do not treat all mental health conditions. Research supports the effectiveness of natural and alternative medicines and therapies, such as the use of methylenedioxymethamphetamine, psilocybin, and other therapies, as safe and effective ways to treat depression, post-traumatic stress disorder, addiction, end-of-life psychological distress, and other afflictions. The purpose of this Act is to establish the beneficial treatments advisory council to review, evaluate, and recommend new medicinal treatments for mental health. SECTION 2. Chapter 321, Hawaii Revised Statutes, is amended by adding a new section to part I to be appropriately designated and to read as follows: "§321- Beneficial treatments advisory council; established. (a) There is established within the department of health for administrative purposes only, a beneficial treatments advisory council. The membership of the council shall be as follows: (1) Five of the members shall be the following ex officio voting members, or their respective designees: (A) The executive director of the office of wellness and resilience, who shall serve as the chairperson of the advisory council; (B) The attorney general; (C) The chairpersons of the senate and house standing committees having responsibility for legislation on health; and (D) The chairperson of the state council on mental health; and (2) Four of the members shall be appointed pursuant to section 26-34 and shall consist of: (A) A physician who is duly licensed pursuant to chapter 453 or an advanced practice registered nurse who is authorized to prescribe psychotropic medication and is duly licensed pursuant to chapter 457; (B) A physician duly licensed pursuant to chapter 453, with specialties in substance abuse and psychiatry; (C) One representative from an organization that advocates for the therapeutic use of plant-based psychedelic modalities; and (D) One representative from an accredited research institution providing certification and training for professionals on the use of psychedelic modalities. (b) The members of the advisory council shall serve without compensation but shall be reimbursed for expenses, including travel expenses, necessary for the performance of their duties. (c) The beneficial treatments advisory council shall: (1) Examine federal, state, and local laws, regulations, administrative rules, and procedures regarding the treatment of mental health; (2) Examine available medical, psychological, and scientific studies, research, and other information relating to the safety and efficacy of methods to treat mental health conditions; (3) Examine requirements, specifications, and guidelines for a medical professional to prescribe and provide various treatments to patients in jurisdictions in which the treatment is used to treat mental health conditions; (4) Develop a long-term strategic plan to ensure the availability of therapeutic psilocybin, psilocybin‑based products, and methylenedioxymethamphetamine that are safe, accessible, and affordable for adults twenty-one years of age or older; and (5) Advise the department on new and revised mental health treatment options." SECTION 3. New statutory material is underscored. SECTION 4. This Act shall take effect on December 31, 2050.
48	48
49	49	SECTION 1. The legislature finds that mental health conditions are treated in various ways, depending on the condition, and can include medication, therapy, and psychosocial services. Congress, through the proposed Breakthrough Therapies Act, and the United States Food and Drug Administration have indicated that methylenedioxymethamphetamine, commonly known as MDMA, and psilocybin will be rescheduled to enable its therapeutic use. Methylenedioxymethamphetamine and psilocybin have already been granted the United States Food and Drug Administration's breakthrough therapy designation to fast-track research and potential approval, given their efficacy in treating treatment-resistant depression and post-traumatic stress disorder. These treatments, while effective for certain conditions and patients, do not treat all mental health conditions. Research supports the effectiveness of natural and alternative medicines and therapies, such as the use of methylenedioxymethamphetamine, psilocybin, and other therapies, as safe and effective ways to treat depression, post-traumatic stress disorder, addiction, end-of-life psychological distress, and other afflictions.
50	50
51	51	The purpose of this Act is to establish the beneficial treatments advisory council to review, evaluate, and recommend new medicinal treatments for mental health.
52	52
53	53	SECTION 2. Chapter 321, Hawaii Revised Statutes, is amended by adding a new section to part I to be appropriately designated and to read as follows:
54	54
55	55	"§321- Beneficial treatments advisory council; established. (a) There is established within the department of health for administrative purposes only, a beneficial treatments advisory council. The membership of the council shall be as follows:
56	56
57	57	(1) Five of the members shall be the following ex officio voting members, or their respective designees:
58	58
59	59	(A) The executive director of the office of wellness and resilience, who shall serve as the chairperson of the advisory council;
60	60
61	61	(B) The attorney general;
62	62
63	63	(C) The chairpersons of the senate and house standing committees having responsibility for legislation on health; and
64	64
65	65	(D) The chairperson of the state council on mental health; and
66	66
67	67	(2) Four of the members shall be appointed pursuant to section 26-34 and shall consist of:
68	68
69	69	(A) A physician who is duly licensed pursuant to chapter 453 or an advanced practice registered nurse who is authorized to prescribe psychotropic medication and is duly licensed pursuant to chapter 457;
70	70
71	71	(B) A physician duly licensed pursuant to chapter 453, with specialties in substance abuse and psychiatry;
72	72
73	73	(C) One representative from an organization that advocates for the therapeutic use of plant-based psychedelic modalities; and
74	74
75	75	(D) One representative from an accredited research institution providing certification and training for professionals on the use of psychedelic modalities.
76	76
77	77	(b) The members of the advisory council shall serve without compensation but shall be reimbursed for expenses, including travel expenses, necessary for the performance of their duties.
78	78
79	79	(c) The beneficial treatments advisory council shall:
80	80
81	81	(1) Examine federal, state, and local laws, regulations, administrative rules, and procedures regarding the treatment of mental health;
82	82
83	83	(2) Examine available medical, psychological, and scientific studies, research, and other information relating to the safety and efficacy of methods to treat mental health conditions;
84	84
85	85	(3) Examine requirements, specifications, and guidelines for a medical professional to prescribe and provide various treatments to patients in jurisdictions in which the treatment is used to treat mental health conditions;
86	86
87	87	(4) Develop a long-term strategic plan to ensure the availability of therapeutic psilocybin, psilocybin‑based products, and methylenedioxymethamphetamine that are safe, accessible, and affordable for adults twenty-one years of age or older; and
88	88
89	89	(5) Advise the department on new and revised mental health treatment options."
90	90
91	91	SECTION 3. New statutory material is underscored.
92	92
93	93	SECTION 4. This Act shall take effect on December 31, 2050.
94	94
95	95	Report Title: Beneficial Treatments Advisory Council; DOH; Mental Health Description: Establishes the Beneficial Treatments Advisory Council to review mental health treatment information and advise the Department of Health. Effective 12/31/2050. (SD2) The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.
96	96
97	97
98	98
99	99
100	100
101	101	Report Title:
102	102
103	103	Beneficial Treatments Advisory Council; DOH; Mental Health
104	104
105	105
106	106
107	107	Description:
108	108
109	109	Establishes the Beneficial Treatments Advisory Council to review mental health treatment information and advise the Department of Health. Effective 12/31/2050. (SD2)
110	110
111	111
112	112
113	113
114	114
115	115
116	116
117	117	The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.